| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/04/2006 | WO2006047639A2 Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| 05/04/2006 | WO2006047638A2 Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease |
| 05/04/2006 | WO2006047637A1 Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections |
| 05/04/2006 | WO2006047515A2 Dendritic cells loaded with heat shocked melanoma cell bodies |
| 05/04/2006 | WO2006047325A1 Method for treating intraocular neovascular diseases |
| 05/04/2006 | WO2006047242A2 Duffy antigen receptor for chemokines and use thereof |
| 05/04/2006 | WO2006047172A1 Tweak receptor |
| 05/04/2006 | WO2006046963A2 Generation of virus-like particles and use as panfilovirus vaccine |
| 05/04/2006 | WO2006046751A1 Anti-glypican 3 antibody having modified sugar chain |
| 05/04/2006 | WO2006046739A1 Remedy for inflammatory diseases |
| 05/04/2006 | WO2006046735A1 Novel aminopyridine derivatives having aurora a selective inhibitory action |
| 05/04/2006 | WO2006046689A1 Remedy for endometriosis |
| 05/04/2006 | WO2006046661A1 Interleukin-6 inhibitor |
| 05/04/2006 | WO2006046143A2 Immunogenic bacterial vesicles with outer membrane proteins |
| 05/04/2006 | WO2006046017A2 Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter |
| 05/04/2006 | WO2006045849A1 T-cadherin antigen arrays and uses thereof |
| 05/04/2006 | WO2006045677A1 Hcv vaccines for chronic hcv patients |
| 05/04/2006 | WO2006045532A2 Virosome particles comprising antigens from influenza virus and hepatitis b virus |
| 05/04/2006 | WO2006045468A1 Combination of a recombinant mycobacterium and a biologically active agent as a vaccine |
| 05/04/2006 | WO2006045308A2 Chlamydia trachomatis antigens for vaccine and diagnostic use |
| 05/04/2006 | WO2006032525A3 Combinational therapy for treating cancer |
| 05/04/2006 | WO2006014953A3 Method for treatment or prophylaxis of a infection using either an antibody which binds to il-9 or an agent which stimulates production of autoantibodies to interleukin-9 |
| 05/04/2006 | WO2006014907A3 Use of parasitic biological agents for prevention and control of allergic and other ige-mediated disorders |
| 05/04/2006 | WO2006009809A3 Vegf inhibitors for the treatment of malignant pleural effusion |
| 05/04/2006 | WO2006005461A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 27 (gpr27) |
| 05/04/2006 | WO2006002438A3 Human monoclonal antibodies to fc gamma receptor i (cd64) |
| 05/04/2006 | WO2006002402A3 Polysaccharide derivatives and uses in induction of an immune response |
| 05/04/2006 | WO2005117974A3 Cancer treatment method by inhibiting mage gene expression or function |
| 05/04/2006 | WO2005117959A3 NEEDLE-FREE ADMINISTRATION OF FeLV BVACCINES |
| 05/04/2006 | WO2005112546A3 Mucinous glycoprotein (muc-1) vaccine |
| 05/04/2006 | WO2005106492A3 Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3) |
| 05/04/2006 | WO2005101966A3 Lipid-extracted therapeutic vaccine and method of use |
| 05/04/2006 | WO2005099668A3 Methods of manufacture and use of calcium phosphate particles containing allergens |
| 05/04/2006 | WO2005090403A3 Method and apparatus for antibody purification |
| 05/04/2006 | WO2005086568A3 Anti-icam-1 human antibodies and uses thereof |
| 05/04/2006 | WO2005084198A3 Peptides of il1 beta and tnf alpha and method of treatment using same |
| 05/04/2006 | WO2005056585A3 Sars coronavirus s proteins and uses thereof |
| 05/04/2006 | WO2005016111A3 Antibodies directed to parathyroid hormone (PTH) and uses thereof |
| 05/04/2006 | WO2004037972A3 Endogenous retrovirus up-regulated in prostate cancer |
| 05/04/2006 | WO2004030610A3 Compositions and methods for the intracellular delivery of antibodies |
| 05/04/2006 | WO2004013311A3 Compositions and methods relating to ovarian specific genes and proteins |
| 05/04/2006 | WO2003097803A3 Cancer-linked gene as target for chemotherapy |
| 05/04/2006 | WO2003037264A3 Therapeutic anti-hiv (vpr) compounds |
| 05/04/2006 | US20060095980 Depletion of endogenous primordial germ cells in avian species |
| 05/04/2006 | US20060094864 Novel polypeptides and nucleic acid molecules encoding those polypeptides; vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, and antibodies which bind to the polypeptides |
| 05/04/2006 | US20060094684 Co-administering the vector with rapamycin; antibodies that block B7-1 & 2, CD28 or CD40L; transgene encodes glucocerebrosidase, alpha-galactosidase A, beta-galactosidase, sphingomyelinase, iduronate sulfatase, alpha-glucosidase, alpha-iduronidase, Factor VIIA, Factor VIII or Factor IX. |
| 05/04/2006 | US20060094683 Immunomodulatory oligonucleotides |
| 05/04/2006 | US20060094682 administering a protein tyrosine kinase inhibitor such as bosutinib, or pyrido(2,3-d)pyrimidine drug known as PD 161570; drug screening; bioassays |
| 05/04/2006 | US20060094674 Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| 05/04/2006 | US20060094056 Method of using cytokine assays to diagnose treat, and evaluate inflammatory and autoimmune diseases |
| 05/04/2006 | US20060094006 Immunotherapy regimens in hiv-infected patients |
| 05/04/2006 | US20060093636 Allantoin-containing skin cream |
| 05/04/2006 | US20060093628 Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride immonomodulator, its production process and formulation |
| 05/04/2006 | US20060093627 Method of protecting chronic infections |
| 05/04/2006 | US20060093626 Lyophilization; conjugated Streptococcus pneumoniae capsular polysaccharide serotype is adjuvanted with 3-0 deacylated monophosphoryl lipid A (3D-MPL) and devoid of aluminium-based adjuvant |
| 05/04/2006 | US20060093625 Light chain that cleaves a neurosecretory protein; an HN domain that translocates the light chain across an endosome membrane and an orphanin polypeptide as a targeting moiety; the HC domain is removed or modified to reduce the targeting of the modified Clostridial toxin to the neuromuscular junction |
| 05/04/2006 | US20060093624 Administering neurotixuns; muscle relaxant; transdermal administering |
| 05/04/2006 | US20060093623 Subtype-matched inactivated whole virus vaccines for treating patients with HIV infection |
| 05/04/2006 | US20060093622 Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same |
| 05/04/2006 | US20060093621 Brucella melitensis strain deficient in the carboxyl-terminal proteolytic processing activity of a tail-specific protease caused by a nucleotide sequence deletion within a tspA gene; vaccine for swine, reindeer, cattle and humans; genetic engineering |
| 05/04/2006 | US20060093620 Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods |
| 05/04/2006 | US20060093617 Peptides for inducing a CTL and/or HTL response to hepatitis C virus |
| 05/04/2006 | US20060093616 Process for vaccinating eucaryotic hosts and for protecting against SARS-CoV infection |
| 05/04/2006 | US20060093615 polypeptide that binds to major histocompatibility complex (MHC) proteins and induces cytotoxic t lymphocytes when bound to MHC antigens; anticancer vaccines |
| 05/04/2006 | US20060093614 Platelet glycoprotein Ib alpha fusion polypeptides and methods of use thereof |
| 05/04/2006 | US20060093613 Soluble T cell receptor |
| 05/04/2006 | US20060093612 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 05/04/2006 | US20060093611 from mammalian chondrocyte progenitor cells expressing mechanosensitive TWIK-related potassium (TREK) ion channels; biocompatability, in vitro |
| 05/04/2006 | US20060093610 Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS 06 of pseudomonas aeruginosa |
| 05/04/2006 | US20060093609 Vaccine against yersinia comprising one or two antibodies, one specific for yersinia pestis f1-antigen and the other one for yersinia pestis v-antigen |
| 05/04/2006 | US20060093608 Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target |
| 05/04/2006 | US20060093607 treatment of mammals susceptible to or diagnosed with cancer, or with relapse tumor growth or relapse cancer cell growth |
| 05/04/2006 | US20060093606 Compositions and methods of using angiopoietin-like 4 protein |
| 05/04/2006 | US20060093605 Expansion of NK cells and therapeutic uses thereof |
| 05/04/2006 | US20060093604 Method of treatment and prophylaxis |
| 05/04/2006 | US20060093603 ErbB4 antagonists |
| 05/04/2006 | US20060093602 Inflammatory mediator antagonists |
| 05/04/2006 | US20060093601 Humanized anti-beta7 antagonists and uses therefor |
| 05/04/2006 | US20060093600 Antibodies to CD40 |
| 05/04/2006 | US20060093599 Anti-properdin antibodies, and methods for making and using same |
| 05/04/2006 | US20060093590 Pseudotyped retroviruses |
| 05/04/2006 | US20060093588 Device for bio-affinity material |
| 05/04/2006 | US20060093582 Listeria-based and LLO-based vaccines |
| 05/04/2006 | US20060093574 Methods for epitope-specific and cytokine/anticytokine combination immunotherapies for modulation of pathogenic immune responses in immune mediated diseases |
| 05/04/2006 | US20060093553 Cd26-based therapies for cancers and immune disease |
| 05/04/2006 | CA2820140A1 Chlamydia trachomatis antigens for vaccine and diagnostic use |
| 05/04/2006 | CA2586019A1 Kinase inhibitors for the treatment of diabetes and obesity |
| 05/04/2006 | CA2585977A1 Remedy for endometriosis |
| 05/04/2006 | CA2585970A1 Mammalian genes involved in infection |
| 05/04/2006 | CA2585717A1 Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| 05/04/2006 | CA2585703A1 Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease |
| 05/04/2006 | CA2585671A1 Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections |
| 05/04/2006 | CA2585638A1 Aminopyridine derivatives having aurora a selective inhibitory action |
| 05/04/2006 | CA2585354A1 Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter |
| 05/04/2006 | CA2585196A1 Anti-glypican 3 antibody having modified sugar chain |
| 05/04/2006 | CA2585011A1 Chlamydia trachomatis antigens for vaccine and diagnostic use |
| 05/04/2006 | CA2584778A1 Immunogenic bacterial vesicles with outer membrane proteins |
| 05/04/2006 | CA2584321A1 Combination of a recombinant mycobacterium comprising a nucleic acid encoding a phagolysosomal escape peptide and an immune response elliciting biologically active agent |
| 05/04/2006 | CA2584305A1 Method for treating intraocular neovascular diseases |
| 05/04/2006 | CA2583677A1 Tnf-like weak inducer of apoptosis (tweak) receptor binding domain |